{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "697148dd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Google API Key loaded successfully.\n",
      "Loading existing vector store from disk...\n",
      "Vector store loaded successfully!\n",
      "Retrieval Question-Answering chain created successfully and now you can start testing the AI.\n"
     ]
    }
   ],
   "source": [
    "# --- STEP ZERO: NETWORK CONFIGURATION FOR WSL ---\n",
    "import os\n",
    "os.environ[\"GRPC_DNS_RESOLVER\"] = \"native\"\n",
    "# --- END OF NETWORK CONFIGURATION ---\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import time\n",
    "import langchain\n",
    "\n",
    "# Load environment variables from the .env file\n",
    "load_dotenv()\n",
    "\n",
    "# Check if the Google API key was loaded\n",
    "if 'GOOGLE_API_KEY' not in os.environ:\n",
    "    print(\"Error: Google API Key not found. Check your .env file.\")\n",
    "else:\n",
    "    print(\"Google API Key loaded successfully.\")\n",
    "\n",
    "# --- Imports for AI libraries ---\n",
    "from langchain_community.document_loaders import DirectoryLoader, PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_huggingface import HuggingFaceEmbeddings\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_google_genai import GoogleGenerativeAI\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.prompts import PromptTemplate\n",
    "\n",
    "# --- STEP 3.3.3: CREATE OR LOAD THE VECTOR STORE ---\n",
    "# Define the path for the saved FAISS index\n",
    "FAISS_INDEX_PATH = \"faiss_index\"\n",
    "\n",
    "# Define the embedding model to be used.\n",
    "model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "model_kwargs = {'device': 'cpu'} # Use 'cuda' if you have a configured GPU\n",
    "encode_kwargs = {'normalize_embeddings': False}\n",
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=model_name,\n",
    "    model_kwargs=model_kwargs,\n",
    "    encode_kwargs=encode_kwargs\n",
    ")\n",
    "\n",
    "# Check if the vector store already exists\n",
    "if os.path.exists(FAISS_INDEX_PATH):\n",
    "    print(\"Loading existing vector store from disk...\")\n",
    "    # allow_dangerous_deserialization is needed for loading local FAISS indexes\n",
    "    vectorstore = FAISS.load_local(FAISS_INDEX_PATH, embeddings, allow_dangerous_deserialization=True)\n",
    "    print(\"Vector store loaded successfully!\")\n",
    "else:\n",
    "    print(\"No existing vector store found. Creating a new one...\")\n",
    "    # --- STEP 3.3.1: LOAD THE KNOWLEDGE BASE ---\n",
    "    loader = DirectoryLoader('./knowledge_base/', glob=\"./*.pdf\", loader_cls=PyPDFLoader)\n",
    "    documents = loader.load()\n",
    "    print(f\"Total documents loaded: {len(documents)}\")\n",
    "\n",
    "    # --- STEP 3.3.2: SPLIT DOCUMENTS INTO CHUNKS ---\n",
    "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=150)\n",
    "    texts = text_splitter.split_documents(documents)\n",
    "    print(f\"Total text chunks created: {len(texts)}\")\n",
    "\n",
    "    # Create the FAISS vector store from the text chunks and the embedding model.\n",
    "    print(\"\\nCreating embeddings and vector store... This might take a moment.\")\n",
    "    vectorstore = FAISS.from_documents(texts, embeddings)\n",
    "    print(\"Vector store created successfully!\")\n",
    "\n",
    "    # Save the vector store to disk for future use\n",
    "    vectorstore.save_local(FAISS_INDEX_PATH)\n",
    "    print(f\"Vector store saved to disk at: {FAISS_INDEX_PATH}\")\n",
    "\n",
    "\n",
    "# --- STEP 3.3.4: CONFIGURE THE LLM AND THE RETRIEVAL CHAIN ---\n",
    "# Configure the LLM that will be used to generate answers\n",
    "llm = GoogleGenerativeAI(model=\"gemini-2.5-flash-lite\", temperature=0.3)\n",
    "\n",
    "# Create a prompt template to instruct the LLM on how to behave\n",
    "prompt_template = \"\"\"\n",
    "Use the following context to answer the question in a detailed and precise manner.\n",
    "If the answer is not in the context, say \"The information is not available in my knowledge base.\"\n",
    "\n",
    "Context:\n",
    "{context}\n",
    "\n",
    "Question:\n",
    "{question}\n",
    "\n",
    "Answer:\n",
    "\"\"\"\n",
    "PROMPT = PromptTemplate(template=prompt_template, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "# Create the Retrieval Question-Answering chain\n",
    "qa_chain = RetrievalQA.from_chain_type(\n",
    "    llm=llm,\n",
    "    chain_type=\"stuff\",\n",
    "    retriever=vectorstore.as_retriever(search_kwargs={\"k\": 3}), # Retrieve the 3 most relevant chunks\n",
    "    return_source_documents=True,\n",
    "    chain_type_kwargs={\"prompt\": PROMPT}\n",
    ")\n",
    "\n",
    "print(\"Retrieval Question-Answering chain created successfully and now you can start testing the AI.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "311bae63-c6e1-4482-9c68-eaed17d74f4c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "--- Testing the AI Assistant ---\n",
      "\n",
      "Question 1: What are the primary challenges in diagnosing MASH, and how do non-invasive tests (NITs) like the FIB-4 score address these challenges?\n",
      "Answer 1: The primary challenges in diagnosing MASH are:\n",
      "\n",
      "1.  **Silent Nature of the Condition:** MASH is a silent condition, meaning most patients do not experience symptoms in the early stages. This leads to 9 out of 10 cases remaining undiagnosed, even in individuals with risk factors like obesity and type 2 diabetes. The disease often progresses to later stages before diagnosis.\n",
      "\n",
      "2.  **Low Medical Familiarity with Diagnostic Methods:** Despite the availability of non-invasive tests (NITs) like FIB-4 and hepatic elastography, which allow for liver evaluation without a biopsy, these methods are underutilized in clinical practice. Many health professionals are unaware of these options or lack access to them.\n",
      "\n",
      "3.  **Lack of Widely Disseminated Clinical Guidelines:** The guidelines for screening and managing MASH are not well-known among health professionals. This lack of awareness creates uncertainty regarding when to investigate and how to manage patients, particularly in primary care settings.\n",
      "\n",
      "4.  **Structural and Access Barriers:** While not explicitly detailed in the provided text, structural and access barriers are mentioned as a contributing factor to diagnostic challenges.\n",
      "\n",
      "Non-invasive tests (NITs) like the FIB-4 score address these challenges by providing simple and effective methods for evaluating the liver without the need for a biopsy. The FIB-4 score, in particular, is identified as a first-line NIT that can be calculated, mostly in primary care and endocrinology settings. It helps in risk stratification and distinguishing between \"lower-risk MASLD\" (suggestive of stage 1 fibrosis or less) and \"at-risk MASH\" (suggestive of stages 2 or 3 fibrosis). Patients with a FIB-4 score of ≥1.3 (or ≥2.0 for those aged 65 and above) require further assessment by specialized healthcare professionals. This approach aims to identify individuals who need more in-depth evaluation, thereby overcoming the limitations posed by the silent nature of MASH and the lack of widespread familiarity with diagnostic methods.\n",
      "\n",
      "Question 2: According to the provided Brazilian guidelines, what is the recommended screening and follow-up protocol for MASLD in overweight or obese individuals?\n",
      "Answer 2: The provided context does not detail a specific screening and follow-up protocol for MASLD in overweight or obese individuals according to Brazilian guidelines. It mentions that the guidelines were developed based on a literature search and include recommendations on screening, diagnosis, treatment, and follow-up. However, the specific steps of the protocol are not outlined.\n",
      "\n",
      "The context does state the following regarding screening:\n",
      "*   For individuals of Asian origin in Brazil, a lower cut-off value for screening should be considered, with a suggestion to screen adult individuals with a BMI > 23 kg/m².\n",
      "*   Abdominal ultrasonography is recommended as a method for screening of hepatic steatosis in patients with overweight/obesity. It is described as the initial method for MASLD screening due to being noninvasive, relatively inexpensive, and easily accessible.\n",
      "\n",
      "Question 3: What is the global prevalence of MASH, and how does it differ in Latin America compared to the rest of the world?\n",
      "Answer 3: The global prevalence of MASH is estimated to be between 3% to 5%, with the most recent guidelines estimating it to be 5.27% (5%–7%). In Latin America, the prevalence of MASH is 7.1%, which is above the world average.\n",
      "\n",
      "Question 4: What lifestyle modifications are recommended for the management of MASLD, and what is the evidence for their effectiveness?\n",
      "Answer 4: The lifestyle modifications recommended for the management of MASLD include a healthy diet and increased physical activity.\n",
      "\n",
      "Regarding the evidence for their effectiveness:\n",
      "*   **Weight Reduction:** A weight reduction of 3-5% is recommended for MASLD with overweight/obesity. For MASLD with class II or III obesity, a weight reduction of >-10% is suggested to improve fibrosis. However, only a limited proportion of individuals achieve a weight reduction of >-5%.\n",
      "*   **Long-term Adherence:** Long-term adherence to behavioral changes is often insufficient, similar to what is observed in obesity trials.\n",
      "*   **Dietary Interventions:** There is limited data on long-term dietary interventions in MASLD, with study durations ranging from 2-24 months. A few studies with 12-24 month follow-ups have shown maximal weight loss at 6 months, followed by gradual weight regain to a net weight loss of about 5% at 12-24 months and partial regain of liver lipid.\n",
      "\n",
      "The context also mentions that greater awareness and improved management of MASLD could decrease health care costs, reduce the need for liver transplantation, and improve health-related quality of life, implying the importance of these lifestyle modifications.\n",
      "\n",
      "Question 5: What are the key recommendations for the pharmacological treatment of MASH, including the use of resmetirom?\n",
      "Answer 5: Based on the provided context, here are the key recommendations for the pharmacological treatment of MASH, including the use of resmetirom:\n",
      "\n",
      "*   **Resmetirom for Non-Cirrhotic MASLD:** Treatment with resmetirom may be considered for individuals with MASLD who are non-cirrhotic and have documentation of either:\n",
      "    *   Advanced fibrosis.\n",
      "    *   At-risk steatohepatitis with significant fibrosis (confirmed by liver biopsy or validated non-invasive panels).\n",
      "    *   Risk of adverse liver-related outcomes (as defined by elastography or biomarker thresholds).\n",
      "    This recommendation is based on Level of Evidence 3 and is an open recommendation.\n",
      "\n",
      "*   **No Current MASH-Targeted Pharmacotherapy for Cirrhotic MASH:** Currently, no MASH-targeted pharmacotherapy can be recommended for adults with MASH at the cirrhotic stage. This is based on Level of Evidence 5 and is a weak recommendation.\n",
      "\n",
      "*   **Vitamin E Not Recommended:** Vitamin E cannot be recommended as a MASH-targeted therapy due to the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis from large phase III trials, as well as potential long-term risks. This is based on Level of Evidence 2 and is a weak recommendation.\n",
      "\n",
      "**General Considerations for MASH Therapies:**\n",
      "\n",
      "*   **Assessment of Comorbidities and Efficacy:** The efficacy of MASH-targeting therapies in individuals with MetALD needs to be thoroughly assessed, with a focus on liver-related outcomes or their surrogates.\n",
      "*   **Defining Non-Response and Stopping Rules:** With the registration of resmetirom and potentially other agents, it is important to define non-response and stopping rules.\n",
      "*   **Long-Term Safety Monitoring:** The long-term safety of pharmacological agents, including metabolic (e.g., bone density, endocrine functions), cardiovascular, and oncological (e.g., extrahepatic malignancy) aspects, needs to be ascertained.\n",
      "*   **Combination Therapy Assessment:** Potential additive or synergistic effects of combining drugs intended to treat MASH and/or cardiometabolic comorbidities need to be prospectively assessed.\n",
      "*   **Demonstration of Beneficial Clinical Outcomes:** All pharmacological agents receiving accelerated approval for MASH treatment must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, HCC) in extended phase III clinical trials and real-world data.\n",
      "*   **Monitoring Treatment Response:** Treatment response should be monitored not only by histological improvement (e.g., improvement in LSM from baseline) but also by considering coverage restrictions, safety concerns, side effects, patient preference, or worsening of liver disease.\n",
      "*   **Stopping Treatment:** If MASH appears to be worsening, treatment should be stopped.\n",
      "*   **Treatment Continuation:** For patients with partial improvement or those considered stable, treatment continuation can be considered and individualized.\n",
      "*   **Real-World Monitoring:** The long-term efficacy and safety of resmetirom should be monitored in real-world clinical registries.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# --- STEP 3.3.5: TESTING THE SYSTEM ---\n",
    "print(\"\\n--- Testing the AI Assistant ---\")\n",
    "\n",
    "# Now you can ask questions directly without debug mode for a cleaner output\n",
    "question1 = \"What are the primary challenges in diagnosing MASH, and how do non-invasive tests (NITs) like the FIB-4 score address these challenges?\"\n",
    "print(f\"\\nQuestion 1: {question1}\")\n",
    "response1 = qa_chain.invoke({\"query\": question1})\n",
    "print(f\"Answer 1: {response1['result']}\\n\")\n",
    "\n",
    "question2 = \"According to the provided Brazilian guidelines, what is the recommended screening and follow-up protocol for MASLD in overweight or obese individuals?\"\n",
    "print(f\"Question 2: {question2}\")\n",
    "response2 = qa_chain.invoke({\"query\": question2})\n",
    "print(f\"Answer 2: {response2['result']}\\n\")\n",
    "\n",
    "question3 = \"What is the global prevalence of MASH, and how does it differ in Latin America compared to the rest of the world?\"\n",
    "print(f\"Question 3: {question3}\")\n",
    "response3 = qa_chain.invoke({\"query\": question3})\n",
    "print(f\"Answer 3: {response3['result']}\\n\")\n",
    "\n",
    "question4 = \"What lifestyle modifications are recommended for the management of MASLD, and what is the evidence for their effectiveness?\"\n",
    "print(f\"Question 4: {question4}\")\n",
    "response4 = qa_chain.invoke({\"query\": question4})\n",
    "print(f\"Answer 4: {response4['result']}\\n\")\n",
    "\n",
    "question5 = \"What are the key recommendations for the pharmacological treatment of MASH, including the use of resmetirom?\"\n",
    "print(f\"Question 5: {question5}\")\n",
    "response5 = qa_chain.invoke({\"query\": question5})\n",
    "print(f\"Answer 5: {response5['result']}\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "06b44160-954f-4e9f-b5c8-3f4a18b4cc62",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
